We need your inspirational words for a new project! Share with us.
FDA Approves Enhertu for Unresectable or Metastatic HER2-Low BC
moderators
Posts: 10,333
FDA Approves Enhertu for Unresectable or Metastatic HER2-Low Breast Cancer
Aug 5, 2022
On Aug. 5, 2022, the U.S. Food and Drug Administration approved Enhertu to treat unresectable or metastatic HER2-low breast cancer. Read more...
0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your profile.